Combination of Infliximab and High-Dose Intravenous Immunoglobulin for Toxic Epidermal Necrolysis: Successful Treatment of an Elderly Patient

Table 1

Core physical and laboratory data of the patient at admission. Parameters included in the calculation of the SCORTEN index are indicated in bold; parameters adding to SCORTEN in the present case are indicated in italics (SCORTEN index = 3).

	Patient's; findings	SCORTEN; index
Physical findings at admission
Age (years)	74	〈 +〉
Body surface affected (%)	25	〈 +〉
Pulses/min	78	⟨−⟩
Malignancy (history)	No	⟨−⟩
Temperature (°C)	38.5
Blood pressure systolic/diastolic (mmHg)	140/65
Laboratory findings at admission
Hematocrit (%)	32.7
Hemoglobin (g/dL)	10.7
White blood cell count/mL	3.72  × 10^3
Platelets/mL	221×10^3
Erythrocyte sedimentation rate (mm/h)	17
C-reactive protein (mg/dL)	10.6
Glucose (mg/dL)	208	⟨−⟩
Urea nitrogen (mg/dL)	107	〈 +〉
Creatinine (mg/dL)	1.91
Sodium (mEq/L)	131
Potassium (mEq/L)	4.08
Bicarbonate (mEq/L)	20.1	⟨−⟩
Total serum protein (g/dL)	6.3
Alanine aminotransferase (U/L)	177
Aspartate aminotransferase (U/L)	92
Alkaline phosphatase (ng/mL)	40